An interventional study of AR-based navigation in Brain Neoplasms, Cerebral Aneurysm and Cerebral Arteriovenous Malformation, sponsored by Seoul National University Hospital. Recruiting at 2 sites in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Brain Neoplasms with a site in Korea, Republic of — 10 open to participants now, 12 under way, 3 of them phase 3. Brain Neoplasms · Korea, Republic of.
Among the 52 studies in Brain Neoplasms with a site in Korea, Republic of, this one is the 27th largest by planned enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2026, is one of 14 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 45th registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →10 of the 52 studies in Brain Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Belgium and 10 more countries
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
Iambic Therapeutics, Inc · Sites in Korea, Republic of, United States, France and 5 more countries
Ages 18+
Asan Medical Center · Sites in Korea, Republic of
Ages 18+
Samsung Medical Center · Sites in Korea, Republic of
Women only
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 20 · Phase 3 8 · Phase 4 2
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 100 across the 46 interventional studies, 93 across the 6 observational. Of the 28 that completed or were terminated, 8 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 52 have an industry lead sponsor. The 10 most frequent:
Seoul National University Hospital is the lead sponsor of 1,903 studies on the registry; 276 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Seoul National University Hospital has 8 studies filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Brain Neoplasms with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05776706Seoul National University HospitalClinical Trial for the Validation of AR Based Neuronavigation System | 2026-12-31 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 52 studies in Brain Neoplasms with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test augmented reality (AR) based neuronavigation system in surgeries for patients of brain neoplasm or cerebral vascular disease. The main questions it aims to answer are:
Participants will participate the study after informed consent. When participants undergo surgery for their brain tumor, we will set up 2 types of neuronavigation, conventional navigation system and developed AR based neuronavigation system. Surgeon will plan and conduct surgery based on only conventional navigation system, but 3D errors at several selected points between two types of navigation will be measured and analyzed.
Being developed AR navigation were reported in our following papers:
This study aims to evaluate the accuracy of anatomical localization of a newly developed augmented reality-based neurosurgery navigation. After 3-dimensional (3D) modeling of the brain of a patient with brain tumor or cerebral vascular disease through 3D image segmentation extraction and modeling, the Augmented Reality (AR)-based navigation developed by this research team can be used with a commercially available visualization device, such as iPad, iPhone, and Hololens2, to evaluate the accuracy.
The AR-based navigation obtained approval from the Ministry of Food and Drug Safety of Republic of Korea (class 2 medical device) in February 2022. Through this clinical tria that compare accuracy with existing conventional intraoperative neuronavigation system, we will evaluate whether it shows equivalent performance to replace the existing navigation.
The criteria were revised on the registry on Nov 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
We will set up 2 navigation systems, newly developed AR-based navigation and conventional navigation system, to surgeries of all participants. Surgeons will perform all surgical planning and operations with reference to the conventional navigation system. In this process, the errors of the existing navigation and the newly developed navigation will be measured and compared in 3D at several points, and the points are as follows: 1. Fiducial markers 2. Nasion 3. Tumor's margin (anterior, posterior, superior, inferior)
Device: AR-based navigation
Patient-specific 3D models are generated from preoperative CT using MEDIP PRO and displayed on a tablet (iPad) via MEDIP PRO AR, superimposed on the patient using markerless surface registration. Registration and TRE measurement are video-recorded for retrospective analysis of registration time. The device is used for accuracy evaluation only and does not guide any surgical step.
Target Registration Error (TRE) of AR-based navigation at anatomical landmarks
Linear distance (mm) between the landmark position displayed by MEDIP PRO AR and the actual position on the patient's skin/skull surface, measured directly with a ruler at three fixed landmarks per participant (right Kocher's point, left Kocher's point, glabella). Measured immediately after registration (pre-drape). Reported as mean ± SD or median (IQR) overall and per landmark.
Time frame: Intraoperative, immediately after AR registration before surgical draping on the day of surgery
Registration time of AR-based navigation
Time (minutes, seconds) from AR software launch to completion of registration, determined by retrospective analysis of intraoperative video recording. Reported separately for manual and automatic registration.
Time frame: Intraoperative, on the day of surgery
Post-drape TRE after QR marker-based registration restoration
TRE (mm) at the same three landmarks measured after surgical draping and restoration of registration using QR markers attached to the skin.
Time frame: Intraoperative, immediately after draping, on the day of surgery
Incidence of registration drift after draping
Proportion of landmarks showing visible displacement of the AR overlay of ≥7.5 mm after draping, assessed on a second tablet held in a fixed mount.
Time frame: Intraoperative, immediately after draping, on the day of surgery
Adverse events and device malfunctions
Number and description of adverse events and device errors occurring during AR navigation application.
Time frame: Intraoperative through end of surgery, on the day of surgery
One-step processing time from CT acquisition to 3D model delivery (SNUH only)
Total elapsed time from CT image receipt on the server to delivery of the 3D mesh to the tablet, including automatic segmentation, calculated from system log timestamps. Success of automatic segmentation (no manual correction required) is also recorded.
Time frame: Preoperative, within 24 hours before surgery
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.
Of 310 non-industry interventional studies with no phase under Brain Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 3 months is below that.
Counting every sponsor, half of 321 studies reached it within 64 months; a quarter within 35 and three quarters within 125.
Start moved once since we started tracking on Sep 25, 2026: May 2025 → Sep 2026, on Nov 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital →